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ABSTRACT 
 
 
 
Obstructive sleep apnea (OSA) is characterised by repetitive closure of the upper airway, repetitive 
oxygen desaturations and sleep fragmentation. The prevalence of adult OSA is increasing because of 
a worldwide increase in obesity and the ageing of populations. OSA presents with a variety of 
symptoms the most prominent of which are snoring and daytime tiredness. Interestingly though a 
significant proportion of OSA sufferers report little or no daytime symptoms. OSA has been 
associated with an increased risk of cardiovascular disease, cognitive abnormalities and mental 
health problems. Randomised controlled trial evidence is awaited to confirm a causal relationship 
between OSA and these various disorders. The gold standard diagnostic investigation for OSA is 
overnight laboratory-based polysomnography (sleep study), however, ambulatory models of care 
incorporating screening questionnaires and home sleep studies have been recently evaluated and are 
now being incorporated into routine clinical practice. Patients with OSA are very often obese and 
exhibit a range of co-morbidities such as hypertension, depression and diabetes. Management, 
therefore, needs to be based on a multidisciplinary and holistic approach which includes lifestyle 
modifications. Continuous positive airway pressure (CPAP) is the first line therapy for severe OSA. 
Oral appliances should be considered in patients with mild or moderate disease or those unable to 
tolerate CPAP. New, minimally invasive surgical techniques are currently being developed to achieve 
better patient outcomes and reduce surgical morbidity. Successful long-term management of OSA 
requires careful patient education, enlistment of the family’s support and the adoption of self-
management and patient goal setting principles.   
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INTRODUCTION & BACKGROUND 
 
 
Obstructive sleep apnea (OSA) is characterized by repetitive, partial or complete closure of the upper 
airway resulting in repeated, reversible blood oxygen desaturation and sleep fragmentation. In the 
general population, the prevalence of adult OSA was found in the 1990s to be approximately 20% 
when defined as an apnea hypopnea index (AHI) >5 events/hour of sleep.[1] The prevalence of “OSA 
syndrome”, a clinical entity defined by an elevated AHI in conjunction with daytime sleepiness, was 
estimated to be 4% in adult males and 2% in adult females.[2]  However, given the recent global trend 
for increasing obesity and aging of populations it is likely that there has been a substantial increase in 
the prevalence of OSA. A recent Brazilian study, for example, showedthat one-third of people had an 
AHI >5 (with symptoms) or AHI >15.[3] Several studies have shown a higher prevalence of OSA in 
older individuals;[4] however some studies suggest that OSA in the elderly may be a condition distinct 
from that of OSA in middle age.[5] OSA is more prevalent in males than in females with an 
approximate ratio of 2:1.However, there is little gender difference after the sixth decade. Population-
based studies have suggested a higher prevalence of OSA amongst African-Americans compared to 
Caucasians, even after controlling for body mass index (BMI).[6, 7] Asians develop OSA at a mean 
BMI 2 kg/m2 less than Caucasians. It is thought that the increased susceptibility to OSA in Asians is 
due to differences in craniofacial and upper airway anatomy.[8] 
 
During the last two decades there have been major advances in the understanding of how recurrent 
upper airway obstruction occurs during sleep in OSA.  Obesity is the most important risk factor for 
OSA. An 8 year population-based study with 690 subjects found that a 10% weight gain predicted a 
32% increase in AHI whilst a 10% weight loss predicted a 26% decrease in AHI.[9] A narrowed 
pharyngeal airway due to increased fat deposition in surrounding structures[10] and reduced 
longitudinal traction on the upper airway due to increased abdominal loading[11] predisposes the 
airway to collapse at sleep onset when upper airway dilator muscle tone falls. Other factors that can 
lead to upper airway narrowing are tonsillar hypertrophy, retrognathia and other forms of craniofacial 
constriction. The severity and frequency of obstructive events during sleep is then determined by a 
complex interplay of four main factors: 1) the severity of the underlying anatomic deficiency; 2) the 
intrinsic stability/instability of the respiratory control system (often referred to as “respiratory loop 
gain”); 3) the capacity of the dilator muscles to mount a neuromuscular compensatory response to 
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obstruction; and 4) the intrinsic sensitivity of the individual to arouse from sleep when obstruction 
occurs.[12] Other factors such as the surface tension of the upper airway lining fluid, which may 
influence airway collapsibility, and alcohol and sedating medication, which can suppress protective 
reflexes, may also influence the severity of OSA.[13, 14] 
 
A wide range of clinical manifestations are associated with untreated OSA as shown in Table 1. 
 
Table1. Common symptoms and signs associated with OSA. 
Daytime symptoms:                                                  
• Sleepiness                                                                      
• Morning headache 
• Tiredness and fatigue 
• Reduced vigilance and executive function 
• Memory impairment 
• Depression 
• Impotence 
 
Nocturnal symptoms: 
• Snoring 
• Apneas observed by the bed partner 
• Sudden choking or gasping awakenings/arousals 
 
Common Clinical signs: 
• Obesity which manifests as 
§ Increased neck and /or waist circumference 
§ Oropharynx that is crowded, narrowed or edematous 
§ Large tongue which sits high in the mouth and obscures a view of the 
oropharynx   
 
Less common signs: 
• Retrognathia 
• Tonsillar hyperplasia or hypertrophy 
• Co-existing hypertension 
• Peripheral edema or signs of mild pulmonary hypertension 
 
Snoring (as reported by the bed partner) and excessive daytime sleepiness (EDS) are the most 
common symptoms that lead patients to seek medical attention. However, perception and reporting of 
daytime sleepiness seem to vary greatly among individuals and subjective tools to measure EDS, 
such as the Epworth Sleepiness Scale (ESS), do not correlate well with the severity of OSA.[15] 
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 DIAGNOSIS 
The diagnosis and decisions regarding treatment of OSA require consideration of potential risk 
factors, severity and impact of patient symptoms, bed partner history, medical co-morbidities plus the 
number of sleep disordered breathing events and severity of oxygen desaturation detected during 
overnight sleep monitoring. A number of screening questionnaires and clinical prediction tools have 
been developed to help identify patients at high risk for OSA who may benefit from more urgent 
evaluation and treatment. Examples of screening tools developed for use in the sleep clinic setting 
include the Multivariable Apnea Risk (MAP) index[16] (based on snorting and gasping, loud snoring, 
breathing cessation, BMI, age and sex), and the Sleep Apnea Clinical Score[17] (SACS) (based on 
neck circumference, hypertension, habitual snoring and partner reports of nocturnal choking or 
gasping). Researchers have also evaluated the role of anatomical measures of the upper airway and 
craniofacial structures in the prediction of OSA risk[18, 19]including the use of quantitative analysis of 
facial photographs.[20] OSA screening tools have also been designed for use outside of the sleep 
clinic setting. These include the STOP questionnaire[21] which was developed for patients attending 
surgical pre-operative assessment clinics, and the OSA50[22] (based on waist circumference, 
snoring, witnessed apneas and age≥50) and Berlin questionnaires[23] which were created for use in 
the primary care population. 
 
The current standard for confirmation of a diagnosis of OSA is laboratory polysomnography (PSG) 
which includes a comprehensive recording of electroencephalography (EEG), electroocculography 
(EOG) and chin electromyography (EMG) to identify sleep stages, as well as airflow, respiratory effort, 
body position, limb movements, electrocardiography (ECG) and oxygen saturation. Cessation of 
airflow for at least 10 seconds is defined as an apnea. A hypopnoea is a ≥10 second reduction in 
airflow associated with an EEG arousal or oxyhaemoglobin desaturation. The apnea hypopnea index 
is the number of apneas and hypopneas per hour of sleep and is the key measure used for 
quantifying disease severity and for defining disease prevalence in normal and clinical populations. 
Several definitions for hypopnea have been proposed and are in clinical use.[24, 25] These can 
markedly affect the AHI value.[25] Thus, care should be taken when comparing research and clinical 
studies between laboratories.    
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 A growing number of portable sleep monitoring systems are being developed for use in a patient’s 
own home without the need for an attending sleep technician. Many of these exclude the recording 
channels used for scoring sleep.  In 1994, the task force for the Standards of Practice Committee of 
the American Sleep Disorders Association (now the American Academy of Sleep Medicine [AASM]) 
classified the different types of sleep apnea evaluation studies into 4 levels according to the number 
of parameters recorded and the presence or absence of attending personnel:[26] 
Type 1:  Standard in-laboratory polysomnography, performed with an attending sleep technician, with 
a minimum of 7 recording channels (EEG, EOG, chin EMG, ECG, airflow, respiratory effort and 
oxygen saturation).Additional channels for detection of snoring and body position are also usually 
employedand video monitoring is sometimes included if a parasomnia is suspected. 
Type 2:  Unattended, comprehensive, portable polysomnography with a minimum of 7 recording 
channels as per type 1. 
Type 3:  Modified portable sleep apnea testing, with a minimum of 4 recording channels (ECG or 
heart rate, oxygen saturation, and at least 2 channels of respiratory movement or respiratory 
movement and airflow). 
Type 4: Continuous recording using 1 to 3 recording channels (usually includes pulse oximetry). 
 
In 2007, the Portable Monitoring Task Force of the American Academy of Sleep Medicine (AASM) 
published clinical guidelines for the use of unattended portable monitors in the diagnosis of OSA 
based on a review of the literature.[27] It was recommended that unattended, portable monitoring 
(recording a minimum of airflow, respiratory effort and oximetry) could be used as an alternative to 
PSG for the diagnosis of OSA in patients with a high pre-test probability of moderate-to-severe OSA 
and without significant medical co-morbidities, in conjunction with a comprehensive evaluation by a 
qualified sleep specialist. It states that portable monitoring devices must allow display of raw data for 
manual scoring or editing prior to automated analysis, and should be reviewed by a sleep specialist. 
The guidelines also provide recommendations regarding the acquisition, analysis and interpretation of 
data and need for appropriate policies and procedures including a quality improvement program to 
assure reliability and validity of testing. Based on these recommendations, the Centers for Medicare 
and Medicaid Services in the United States have approved the use of a limited home sleep recording 
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device with at least 3 channels to diagnose OSA for the purposes of reimbursement for CPAP 
treatment.  
 
There has been increasing interest in simplified, ambulatory models for diagnosing OSA that combine 
the use of screening questionnaires and limited sleep monitoring. In a randomised controlled trial 
evaluating an ambulatory management strategy for OSA, Mulgrew et al[28] applied a simplified 
diagnostic algorithm to identify patients with moderate-severe OSA in a sleep clinic population based 
on an ESS ≥10, SACS ≥15 and oxygen desaturation index ≥15/hour on overnight home oximetry, 
followed by auto-adjusting positive airway pressure (APAP) titration to determine a fixed treatment 
pressure for ongoing CPAP therapy. Of the patients who scored positively on the diagnostic algorithm 
and who underwent subsequent PSG, 94% (95%CI: 81-99%) were correctly identified as having an 
AHI>15/hr. In our own research work, we have evaluated the accuracy of a simplified diagnostic 
strategy for OSA in a primary care population consisting of the OSA50 questionnaire followed by 
overnight oximetry.[22] We found that the simple two-step model could identify moderate-severe OSA 
with a high degree of accuracy, with a sensitivity of 88% and specificity of 82%. In deploying these 
simplified diagnostic algorithms it is important to remember that the pre-test probability of disease can 
have a substantial influence on the post-test probability of disease. Thus ideally they should be 
validated within the population of intended application before use or, as a minimum, the pre-test 
probability of disease estimated and taken into account in the interpretation of results. The final test of 
whether simplified diagnostic algorithms are effective and safe is to determine whether patient 
outcomes using these methods are the same or similar to those used in more conventional sleep 
specialist laboratory-based services. Several recent studies have reported encouraging results using 
such methods, finding non-inferior or non-significant differences for patient outcomes including sleep 
apnea symptoms and sleep related quality of life.[28-33] 
 
NEUROBEHAVIOURAL, CARDIOVASCULAR AND METABOLIC 
ABNORMALITIES ASSOCIATED WITH OSA 
Excessive daytime sleepiness is the cardinal symptom of OSA and is thought to be the main reason 
for the 2-5 fold increased risk of motor vehicle accidents observed amongst OSA patients.[34]Daytime 
sleepiness is also a major contributor to the reduced quality of life, mood disturbance, decreased work 
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performance and increased occupational accidents reported by OSA patients. It is important to 
remember, however, when assessing patients for snoring and possible sleep apnoea that (a) most 
subjects identified with OSA in population studies do not report daytime sleepiness[35, 36] and (b) 
there is an extensive list of causes of self-reported sleepiness apart from OSA[37] (e.g. depression, 
lifestyle-related chronic sleep loss, sedating medication and non-respiratory medical co-morbidities) 
which can impact on a patient and may even be the dominant cause of their sleepiness.   
 
There has been a great deal of interest over the last two to three decades in the possibility that OSA 
may lead to hypertension, diabetes, hyperlipidaemia, stroke, coronary artery disease and increase 
mortality.[38] Early data from animal experiments which employed repetitive hypoxia in an attempt to 
mimic the gas exchange disturbance of OSA showed marked systemic hypertension.[39] Similar 
experiments have shown derangements in lipid metabolism, including accelerated atherosclerosis, 
and altered glucose metabolism.[40] Thus it appears biologically plausible, at least, that a patient with 
OSA might be at increased risk of cardiovascular and metabolic disease.  
 
Early cross-sectional, population studies suggested that OSA may be a risk factor for hypertension, 
independent of other known risk factors.[41] However, the results from longitudinal studies have been 
less convincing. Two studies showed that OSA independently predicted incident hypertension[42, 43] 
while two other studies did not.[44, 45]  There have been a relatively large number of small 
randomised controlled trials (RCTs) of CPAP and mandibular advancement therapy[46] for OSA, 
which have reported the effects on blood pressure. Meta-analyses have shown reductions of 
approximately 2 mmHg in both systolic and diastolic blood pressure.[47] A criticism of these earlier 
studies and a suggested reason for the small OSA-treatment related reductions in blood pressure was 
that most patients included in the trials were normotensive. However, similar results have 
subsequently been reported in RCTs which enrolled newly diagnosed OSA patients with untreated 
hypertension.[48, 49] At the present time we can conclude that OSA elevates blood pressure but the 
effects appear to be relatively modest. Mild pulmonary artery hypertension also appears to be caused 
by OSA.[50] 
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While the sustained effects of OSA on blood pressure appear to be quite modest, acute fluctuations in 
blood pressure at night secondary to the repetitive obstructed breathing events, episodic hypoxia and 
hypercapnia and autonomic instability are relatively large (i.e. 10-20mmHg). It is possible that these 
acute OSA-induced physiological changes combined with the increased after-load and stretch placed 
on the heart during obstructed breathing could lead to acute ischaemic events or arrhythmias during 
sleep, particularly in individuals with pre-existing cardiac disease.[51] Studies have shown that OSA 
patients who suffer an acute myocardial infarction or who die suddenly from cardiac causes are more 
likely to do so during the night-time hours than in the morning after rising as is usually the case.[52, 
53]Epidemiological evidence suggests that OSA may be an independent risk factor for future strokes, 
heart failure, atrial fibrillation, ischaemic heart disease and cardiovascular mortality.[54-58] However, 
the evidence is not consistent between studies with some studies suggesting that only middle aged 
men, and not older men or women, are at risk.[55, 56, 58] 
 
Small, short-term RCTs conducted in patients with OSA on CPAP therapy have generally shown 
inconsistent effects on glucose and lipid metabolism.[59] However, a recent well controlled cross-over 
RCT of CPAP versus sham CPAP in 75 OSA patients with co-existing metabolic syndrome reported 
significant improvements in HbA1c, low density lipoprotein and total cholesterol following OSA 
treatment.[60] 
 
The field is now in need of definitive large-scale randomised controlled trials of OSA treatment that 
focus on hard cardiovascular outcomes. Several trials are currently in progress including the 
multinational Sleep Apnea cardioVascular Endpoints (SAVE) study.[61] 
 
OSA TREATMENT 
A wide range of management options are available for the treatment of OSA ranging from 
conservative measures including lifestyle modifications to reduce weight and alcohol consumption, to 
CPAP, mandibular advancement splints (MAS) and surgical interventions. Treatment choices are 
based on the severity of the patient’s OSA, associated symptoms, co-morbidities, occupation and 
patient preferences.  
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Conservative Treatment and Lifestyle Modifications 
Weight loss via dietary modifications and regular exercise should be recommended to all patients with 
OSA (regardless of severity) who are overweight or obese.[62] Alcohol has been shown to worsen 
OSA by suppressing protective neuromuscular and arousal reflex responses.  Thus, all patients with 
OSA should be advised to avoid heavy alcohol consumption particularly 4-6 hours prior to bed time. In 
addition OSA patients appear to exhibit greater decrements in daytime functioningafter low dose 
alcohol and partial sleep restriction  than non-OSA subjects.[63] They should therefore be 
encouraged to always obtain a full night’s sleep and to limit their alcohol consumption, particularly 
before undertaking potentially hazardous tasks such as driving.  
 
Supine position-dependent OSA is commonly seen in clinical practice and is found in up to one third 
of patients with mild and moderate OSA.[64] Traditionally, a tennis ball strapped to the back while 
sleeping has been used to avoid supine sleep. However, studies suggest that long term compliance 
with this technique is poor, limiting its effectiveness.[65, 66] Newer position monitoring and supine 
alarm devices may be more comfortable to wear at night.  We found in a preliminary study in supine-
predominant OSA patients that one such technique was highly effective in avoiding the supine sleep 
position and in reducing overnight AHI, although it did not decrease overall snoring intensity.[67] 
 
Continuous Positive Airway Pressure (CPAP) 
CPAP is considered the “gold standard” treatment for OSA. It was first described by Sullivan et al in 
1981.[68] CPAP consists of a flow generator which delivers air via tubing and a nasal or oral mask to 
produce a fixed positive pressure in the upper airway. The positive airway pressure (PAP) splints the 
upper airway, preventing repeated collapse and closure, stabilises overnight oxygen saturation and 
reduces sleep fragmentation. Both “fixed” CPAP and auto-adjusting PAP devices are available. 
AutoPAP devices automatically adjust PAP to correct obstructive events and compensate for acute 
changes in posture or long term changes in weight. They appear to confer no particular clinical 
advantage over fixed CPAP devices for long term treatment except perhaps in patients who require a 
high inflating pressure.[69] However, a short ambulatory study over several nights using an autoPAP 
device is a useful alternative to an in-laboratory, overnight, manual titration to enable a “fixed” CPAP 
level to be estimated to treat OSA.    
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 A systematic meta-analysis of 36 RCTs has shown effectiveness of CPAP in reducing AHI, symptoms 
of sleepiness and improving quality of life measures in people with moderate to severe OSA.[70]The 
evidence regarding the effect of CPAP on neuropsychological outcomes has been mixed with some 
RCTs demonstrating improvement in some outcomes[71] but other studies showing no significant 
improvement in neurocognitive functioning.[72] 
 
CPAP Acceptance and Adherence   
A significant proportion of patients with moderate to severe OSA reject CPAP treatment outright when 
it is offered. Cost may be a barrier in some health systems but even when this is not an issue initial 
acceptance can be low.  Patients’ knowledge and perceptions of the importance of OSA and the 
necessity of treatment appear to be the major determinants of whether or not they accept CPAP 
therapy.  Unfortunately, amongst those who initially accept CPAP therapy, long- term compliance is 
also relatively poor. In one study, only 68% of patients were using CPAP after 5 years.[73] Other data 
suggest that 50% of patients who initiate CPAP discontinue use within the first year, most of them 
within the first month. Initial acceptance and good long term compliance are obviously vital in order to 
obtain the desired benefits from CPAP. Many studies have defined acceptable compliance as being at 
least 4 hours of usage for more than 70% of nights. However, such definitions are arbitrary and 
studies show a dose-response curve across a wide range of CPAP average nightly use for outcomes 
such as reduced daytime sleepiness.[74]  Effort and resources should be dedicated, particularly in the 
first few weeks of therapy, towards ensuring CPAP acceptance and optimal compliance. Some of the 
strategies to increase CPAP compliance and adherence are listed in Table 2. 
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Table 2:  
Strategies  to maximise CPAP acceptance: 
• Education and provision of written literature at an appropriate level for the patient 
• Regular weekly phone calls for first few weeks  
• Use of nasal humidification 
 
Strategies  to improve suboptimal  CPAP adherence 
• Consideration of CBT and desensitisation 
• Consideration of alternate mask interfaces in case of discomfort or significant leak 
• Consideration of a short course of Eszopiclone at CPAP initiation if no contra-
indications in patients with high risk on non-compliance[75] 
 
 
Oral Appliance Therapy 
A MAS is the most commonly oral appliance used as an alternative to CPAP. Other devices include 
tongue-retaining devices and palatal-lifting devices. A MAS works by advancing the mandible and has 
been shown to decrease AHI[76] and subjective sleepiness.[77]  These devices are usually indicated 
for patients with mild to moderate OSA who prefer it over CPAP or who have tried and failed CPAP 
therapy. MAS devices are generally less effective in reducing the AHI compared with CPAP and are 
generally not indicated as a first line treatment in patients with severe OSA. MAS is contra-indicated 
in some circumstances (Table 3). 
 
 
Table 3. Relative contraindications for MAS. 
 
• Pre-existing temporo-mandibular joint (TMJ) disease or instability 
• Insufficient dentition to support device retention, e.g., less than 6 teeth in each arch 
• Severe bruxism 
• Patient unable to open the mouth adequately 
• Brisk gag reflex 
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Surgical Interventions 
Surgical interventions are generally not indicated as first line treatment and used only when non-
invasive measures have been tried and failed or have been rejected by the patient. Surgical 
interventions can be broadly divided into procedures aimed at curing OSA via upper airway 
reconstruction and interventions to improve CPAP adherence eg improving nasal patency by 
septoplasty or polypectomy. Despite progress and advancements in surgical techniques for the 
treatment of OSA, there is still a lack of good quality data with regard to the effectiveness and 
selection of patients for surgical interventions.[78] 
 
Uvulopalatopharyngoplasty (UPPP) is the most common OSA surgical procedure. It involves 
resection of the uvula, redundant retrolingual soft tissue, and palatine tonsillar tissue.UPPP with or 
without tonsillectomy has not been shown to reliably cure OSA in patients with moderate to severe 
OSAS.[78] An RCT comparing UPPP and conservative management in OSA patients with >50% 
obstruction at the palatal level showed improvement in daytime sleepiness and oxygen desaturations 
at one year, however, only 38% achieved normality of their oxygen desaturation index at 1 year.[79] 
The surgical complication rate was 22%.Maxillomandibular advancement (MMA) involves forward-
fixing the maxilla and mandible. A meta-analysis which included data from several case series 
suggested MMA to be more consistent in reducing AHI compared with the other surgical techniques, 
however, a high risk of bias and the heterogeneity of the studies were limiting factors of this meta-
analysis.[80] 
 
 
 There are a variety of procedures to reduce or advance the tongue base.  Submucosal 
radiofrequency or bipolar techniques are relatively easy, well-tolerated and low-risk, but only 
partially effective for treating sleep apnea.[81] Hypoglossal nerve stimulation is a new treatment 
currently under evaluation which leads to contraction of the genioglossus muscle, tongue protrusion, 
stiffening of the anterior pharyngeal wall and an increase in upper airway diameter. A recent RCT of 
an implantable hypoglossal nerve stimulation system in 21 patients with moderate to severe OSA who 
were intolerant of CPAP, showed a success rate (as defined by 50% reduction in AHI with an AHI of 
<20/hr) of 67% at 6 months.[82] This was associated with significant improvement in ESS. However 
studies showing benefit in larger patient samples and after longer periods of follow-up are required 
before this therapy can be adopted as part of routine clinical practice.  
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 Other Novel Therapies Currently Under Evaluation 
Acetazolamide has been shown to reduce the respiratory loop gain by approximately 40% in 
individuals with OSA,[83] however, there is insufficient evidence to recommend its clinical use in 
patients with OSA at this time. Similarly, eszopiclone has been shown to improve OSA patients with a 
low arousal threshold[84] but confirmatory studies are needed to confirm its efficacy and safety. A 
disposable nasal one-way valve device designed to preferentially increase expiratory airway pressure 
has recently been shown to reduce AHI and improve subjective sleepiness when compared to sham 
treatment in patients with mild to severe OSA.[85] However, more long-term data on efficacy, 
adherence and cost-effectiveness is required before its role in the routine management of OSA can 
be determined. 
 
 
OTHER SLEEP –RELATED BREATHING DISORDERS: 
A detailed discussion of all the sleep-related breathing disorders is beyond the scope of this review, 
however, a brief note about some of the more relevant conditions which may co-exist with OSA is 
worthwhile. Central sleep apnea (CSA) is characterized by repetitive, complete cessation of airflow 
and ventilatory effort during sleep (compared with OSA, in which ventilatory effort persists). CSA may 
be idiopathic, however, common risk factors include heart failure (usually associated with Cheyne-
Stokes respiration [CSR,or crescendo-decrescendo breathing], opiate use and stroke). The mainstay 
of treatment of CSA is control of the underlying or predisposing risk factor. Positive pressure mask 
therapies have also been used. While the intention-to-treat analysis of a multicentre RCT of CPAP 
therapy for CSR in patients with heart failure was negative with respect to the primary outcome of 
mortality,[86] CPAP treatment was highly variable in its effect on the sleep-disordered breathing, 
ranging from virtually no effect to complete suppression of central apneas. A post hoc analysis 
suggested there was clinical benefit in the subset of patients in whom central apnea was 
supressed.[86, 87]  Thus there is some evidence for the role of CPAP therapy in patients with CSA 
related to heart failure but a newer treatment, adaptive servo-controlled ventilation (ASV), a “smart” 
form of bi-level positive pressure mask ventilator support which normalises ventilation by adjusting the 
level of ventilatory support breath-by-breath according to the patient’s pattern of breathing) may prove 
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in the long term to be more effective. Two international, multicentre RCTs of ASV to treat sleep 
disordered breathing in patients with heart failure are currently in progress (SERVE-HF, ADVENT-HF)  
Bi-level positive airway pressure (BIPAP) with a back-up respiratory rate is also an option for 
treatment of symptoms and/or respiratory failure in patients with CSA related to CNS suppression 
(e.g. resulting from CNS disease). Complex sleep apnea refers to a condition in which CSA 
persists or emerges following the application of CPAP for OSA, This occurs in approximately 10% of 
patients with OSA[88] and may be a transitory phenomenon that disappears after several weeks of 
CPAP treatment.[89] However, in a small proportion of patients it can persist and limit the 
effectiveness of therapy. In severe cases, a trial of bi-level pressure support with a back-up rate 
should be considered or, alternatively, adaptive servo-controlled ventilation. Overlap syndrome 
refers to the combination of Chronic Obstructive Pulmonary disease (COPD) and OSA.[90] These 
patients are at increased risk of hypercapnic respiratory failure and pulmonary hypertension 
compared with patients who have OSA or COPD alone[91] and may be at greater risk of COPD 
exacerbations and premature death.[92]Management should include a trial of CPAP and, in the case 
of a suboptimal response or worsening respiratory failure, institution of nocturnal BIPAP with or 
without supplemental oxygen. Sleep-related hypoventilation can occur in the absence of OSA if 
there is severe mechanical impairment to respiration imposed by morbid obesity or neuromuscular 
disease and can cause progressive respiratory failure. The reader is directed to several recent 
reviews which describe the prevalence, pathogenesis and clinical management of this group of 
disorders.[93, 94] 
 
OSA AS A CHRONIC CONDITION AND OSA CHRONIC CARE 
MODEL  
OSA is a common disorder that meets the characteristics of a chronic disease as it is a disease which 
is prolonged, does not resolve spontaneously and is rarely completely cured.[95] Thus OSA requires 
ongoing management of residual symptoms, deficits and comorbidities. Furthermore many OSA 
patients have modifiable lifestyle factors that contribute to their disease, which could be improved with 
interventions. The recent American Academy of Sleep Medicine guideline for OSA shows support for 
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approaching OSA as a chronic disease requiring long term multidisciplinary management and this is 
an important future direction for the care of patients with OSA.[62] 
 
There are a number of common co-morbidities seen in OSA patients. Some contribute independently 
to one of the commonest presenting complaints, EDS and several have the potential to influence 
patient outcomes on CPAP. 
 
Obesity is an extremely common and important cause of OSA as mentioned earlier[9] and effective 
therapies for obesity, e.g. bariatric surgery, lead to significant improvements in OSA.[96] Obesity has 
also been associated with EDS, independent of OSA.[37] Depression is also common amongst 
patients with OSA, the reported prevalence being between 21 and 41%.[97] Like obesity, depression 
may contribute to EDS, independent of OSA. In a population-based study, Bixler and colleagues 
found that depression was the most significant risk factor for EDS followed by BMI, age, typical sleep 
duration, diabetes, smoking, and finally obstructive sleep apnea.[37] 
 
Alcohol intake is an important modifiable risk factor for OSA. Alcohol, particularly in the last two hours 
before bed-time, increases the duration and frequency of obstructive episodes, and worsens OSA. 
Other common comorbidities in OSA patients are hypertension, cardiovascular disease and type 2 
diabetes mellitus.[98, 99] 
 
While CPAP is the gold standard treatment for moderate-severe OSA, some residual symptoms and 
deficits remain even among those who appear to be optimally treated. We conducted a multicentre 
study of 174 patients treated with CPAP and found that 40% of moderate-severe OSA patients still 
had an abnormal ESS score after three months of CPAP treatment.[74] Very similar results were 
reported by Weaver and colleagues in 2007.[100] 
 
This residual excessive daytime sleepiness may have various aetiologies such as disruption to sleep 
caused by CPAP itself, insufficient use of CPAP, other sleep disorders not responsive to CPAP, co-
existent mood disorders, sedating medications, obesity, advanced age, insufficient sleep duration, 
diabetes, smoking or hypoxic brain injury from chronic OSA. Depression is a particularly important co-
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morbidity to consider when treating OSA, given the overlap between symptoms and the strong 
association between the two.[37, 97] A broader approach to the recognition, diagnosis and 
management of EDS is warranted and should be part of chronic condition management in OSA. 
 
The Chronic Care model has been accepted as a conceptual framework to re-organise patient care to 
meet the needs of people with chronic illness and is ideal for use in a chronic condition such as 
OSA.[101] The model is comprised of four components: (1) ongoing self-management support; (2) 
delivery system features such as planned visit schedules and multidisciplinary collaborative care 
arrangements; (3) decision supports such as guidelines, access to experts and reminder systems; 
and (4) clinical information systems which provide timely data about individual patients and 
populations. The important role of self-management support in the chronic care model is justified by 
the recognition that patients themselves and their families are the primary caregivers in chronic 
illness.[102] 
 
When constructing such a chronic care model, health literacy must be considered. Health literacy 
includes the ability to read, write and understand health-related information, to make sound health 
related decisions and to navigate life in a way that promotes good health. A recent Australian survey 
indicated that around 60% of adults lacked the health literacy skills to cope with the demands of 
modern health care and to make the decisions required to manage their health.[103] 
 
In summary, there are many disease management issues for patients with OSA, including: factors 
known to contribute to OSA severity and multiple co morbidities, residual daytime sleepiness despite 
CPAP therapy and inadequate CPAP adherence. All of these disease management issues are ideally 
addressed as part of a comprehensive chronic condition management program. 
 
It is our view that if Sleep Medicine services focus their therapeutic interventions for OSA solely 
around devices (CPAP, MAS etc) and do not incorporate chronic disease management programs into 
the care pathways of those with OSA, patient outcomes will remain below expectations.  
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SUMMARY 
Adult OSA is a chronic condition, the prevalence of which is increasing with the increasing trend of 
obesity and ageing. In addition to obesity, various other anatomical and physiological factors also play 
a role in the pathogenesis of OSA including craniofacial features, respiratory control system stability 
(loop gain), arousal threshold and upper airway dilator muscle activity. Laboratory-based 
polysomnography is the gold-standard diagnostic test, however, home based studies could be 
performed in selected patients with a sleep specialist follow up. Various models of screening and 
home based sleep studies have been proposed and are under investigation. CPAP should be 
considered as first line treatment in patients with severe OSA, and, moderate OSA with symptoms. 
Second line management options include oral appliances and surgical interventions. Further research 
has been undertaken to evaluate potential new treatment modalities, however, data on their 
effectiveness are currently limited. OSA management should be based on a holistic approach, 
keeping in mind other co-morbidities and should involve the patient and their family in decision 
making. 
 
MAIN MESSAGES 
 
• In the general population, one in every five persons has an AHI > 5/hour.  
• Obesity and increased waist circumference are the most important risk factors for OSA. However, 
other factors including craniofacial anatomy, stability of respiratory control centre, upper airway 
dilator muscle activity are also considered to contribute to the pathogenesis of OSA. 
• Various OSA screening tools are increasingly being used to identify people at high risk of OSA in 
the population. 
• In-laboratory polysomnography is the current standard for diagnosis of OSA. 
• Home-based polysomnography can be considered as an alternative in selected patients with high 
pre-test probability and without significant co-morbidities in conjunction with a sleep specialist 
review. 
• Untreated OSA is associated with a modest increase in blood pressure and causes mild 
pulmonary hypertension.  
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• OSA has been found to be independent risk factor for ischemic heart disease, stroke and overall 
cardiovascular mortality, particularly in middle-aged men. However, there is a need for good 
quality treatment intervention studies to see whether OSA treatment can reduce these risks. 
• OSA should be managed as a chronic condition with a multidisciplinary approach and 
involvement of the patient, their family and relevant health professionals. 
• CPAP is the first line therapy for severe OSA. Oral appliance therapy and surgical interventions 
can be considered in patients with less severe disease or in patients who have difficulty tolerating 
CPAP. 
• Treatment and management of co-existing conditions e.g., insomnia and depression is vital for 
better outcomes. 
• Ongoing follow up with the aim of education, treatment compliance assessment and patient-
tailored management are the key for successful long-term management of OSA. 
 
 
 
MULTIPLE CHOICE QUESTIONS (TRUE/FALSE) 
1)  Concerning OSA prevalence and risk factors: 
A) OSA is more prevalent in males than in females. 
B) OSA is more prevalent amongst Caucasians than AfricanAmericans. 
C) When matched for disease severity Asians will develop OSA at a BMI that is 4kgms/m2 less 
than in Caucasians. 
D) Weight loss of 10% can reduce the AHI by approximately 26%. 
E) Alcohol is an important modifiable risk factor for OSA. 
 
2)   The following are symptoms that could be associated with OSA: 
A) Fatigue & tiredness 
B) Reduced vigilance and executive function 
C) Memory impairment 
D) Impotence 
E) All of the above 
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3)  Regarding the diagnosis of OSA: 
A) ECG is not a part of the standard in-laboratory polysomnography. 
B) An apnea is defined as cessation of airflow for atleast 10 seconds. 
C) AHI is the number of apneas and hypopneas per hour of sleep. 
D) OSA50 is a validated screening questionnaire based on waist circumference, snoring, 
witnessed apneas and age ≥50. 
E) Home based polysomnography could be an alternative to in-lab study even in complex 
patients with multiple medical co morbidities. 
 
 
4)  OSA associations and consequences: 
A) Drivers with untreated, severe sleep apnea have a higher chance of automobile crash 
compared with other drivers. 
B) Untreated OSA has not been to be associated with pulmonary hypertension. 
C) OSA may be an independent risk factor for systemic hypertension. 
D) OSA may be an independent risk factor for heart failure, ischemic heart disease and 
cardiovascular mortality. 
E) Everyone with OSA can expect to feel excessively sleepy 
 
5)  OSA treatment and management: 
A) CPAP is the second-line treatment for severe OSA. 
B) Self management support is a critical part of chronic care model for OSA management. 
C) Underlying depression should be identified and treated. 
D) Alcohol avoidance prior to bed time is usually recommended. 
E) Supine avoidance is ineffective and has no role in the management of positional OSA. 
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 Answer Key: T=True, F=False. 
1) A-T, B-F, C-T, D-T, E-T. 
2) A-T, B-T, C-T, D-T, E-T. 
3) A-F, B-T, C-T, D-T, E-F. 
4) A-T, B-F, C-T, D-T, E-T. 
5) A-F, B-T, C-T, D-T, E-F. 
 
 
 
 
Table 4: CURRENT RESEARCH QUESTIONS 
• Clearer and more detailed understanding of the various physiologic phenotypes of 
OSA. 
• Long-term relationship between OSA and cardiovascular risk /morbidity. 
• Association between OSA and neurocognitive outcomes. 
• Feasibility and effectiveness of various new investigative treatments for OSA. 
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